Noxopharm Initiates First SOF-SKN™ Dose in HERACLES Trial
I'm PortAI, I can summarize articles.
Noxopharm Ltd. has initiated the first dose of its drug candidate SOF-SKN™ in the HERACLES clinical trial, aimed at evaluating its safety for autoimmune diseases, particularly cutaneous lupus erythematosus. This milestone positions Noxopharm to potentially capitalize on the $3 billion global lupus market and expand into other autoimmune conditions. Noxopharm is a clinical-stage biotech company focused on innovative treatments for cancer and inflammation, utilizing its proprietary technology platforms.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments